{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T16:58:50Z","timestamp":1771952330995,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06784-w","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T04:12:24Z","timestamp":1770869544000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Intermediate doses cytarabine after induction with CPX-351 for patients with secondary AML: safety and efficacy"],"prefix":"10.1007","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8196-0481","authenticated-orcid":false,"given":"Salvatore","family":"Perrone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6497-1226","authenticated-orcid":false,"given":"Andrea","family":"Corbingi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1922-5157","authenticated-orcid":false,"given":"Calogero","family":"Vetro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4896-6666","authenticated-orcid":false,"given":"Fanny Erika","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6094-4351","authenticated-orcid":false,"given":"Paola","family":"Minetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9649-6895","authenticated-orcid":false,"given":"Carola","family":"Riva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5642-3051","authenticated-orcid":false,"given":"Laura","family":"Cicconi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8911-3544","authenticated-orcid":false,"given":"Chiara","family":"Vernarecci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9000-562X","authenticated-orcid":false,"given":"Roberto Massimo","family":"Lemoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7429-8004","authenticated-orcid":false,"given":"Alessandro","family":"Pulsoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3166-6078","authenticated-orcid":false,"given":"Fabio","family":"Guolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"6784_CR1","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner H, Weisdorf DJ, Bloomfield CD (2015) Acute myeloid leukemia. N Engl J Med 373:1136\u20131152. https:\/\/doi.org\/10.1056\/NEJMra1406184","journal-title":"N Engl J Med"},{"key":"6784_CR2","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP et al (2022) International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood 140:1200\u20131228. https:\/\/doi.org\/10.1182\/blood.2022015850","journal-title":"Blood"},{"key":"6784_CR3","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O et al (2022) The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia 36:1703\u20131719. https:\/\/doi.org\/10.1038\/s41375-022-01613-1","journal-title":"Leukemia"},{"key":"6784_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14122843","volume":"14","author":"M Molica","year":"2022","unstructured":"Molica M, Perrone S, Mazzone C et al (2022) CPX-351: an old scheme with a new formulation in the treatment of high-risk AML. Cancers 14:2843. https:\/\/doi.org\/10.3390\/cancers14122843","journal-title":"Cancers"},{"key":"6784_CR5","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","volume":"36","author":"JE Lancet","year":"2018","unstructured":"Lancet JE, Uy GL, Cortes JE et al (2018) CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol 36:2684\u20132692. https:\/\/doi.org\/10.1200\/JCO.2017.77.6112","journal-title":"J Clin Oncol"},{"key":"6784_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00361-8","volume":"10","author":"F Guolo","year":"2020","unstructured":"Guolo F, Fianchi L, Minetto P et al (2020) CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program. Blood Cancer J 10:96. https:\/\/doi.org\/10.1038\/s41408-020-00361-8","journal-title":"Blood Cancer J"},{"key":"6784_CR7","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1080\/10428194.2019.1688320","volume":"61","author":"JE Kolitz","year":"2020","unstructured":"Kolitz JE, Strickland SA, Cortes JE et al (2020) Consolidation outcomes in CPX-351 versus cytarabine\/daunorubicin-treated older patients with high-risk\/secondary acute myeloid leukemia. Leuk Lymphoma 61:631\u2013640. https:\/\/doi.org\/10.1080\/10428194.2019.1688320","journal-title":"Leuk Lymphoma"},{"key":"6784_CR8","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1200\/JCO.2004.07.012","volume":"22","author":"JC Byrd","year":"2004","unstructured":"Byrd JC, Ruppert AS, Mr\u00f3zek K et al (2004) Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. J Clin Oncol 22:1087\u20131094. https:\/\/doi.org\/10.1200\/JCO.2004.07.012","journal-title":"J Clin Oncol"},{"key":"6784_CR9","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1159\/000535457","volume":"147","author":"C Jimenez-Chillon","year":"2024","unstructured":"Jimenez-Chillon C, Dillon R, Russell N (2024) Optimal post-remission consolidation therapy in patients with AML. Acta Haematol 147:147\u2013158. https:\/\/doi.org\/10.1159\/000535457","journal-title":"Acta Haematol"},{"key":"6784_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.70083","author":"F Guolo","year":"2025","unstructured":"Guolo F, Fianchi L, Martelli MP et al (2025) Real world study on the best CPX-351 treatment duration and timing for allogeneic stem cell transplantation. Am J Hematol. https:\/\/doi.org\/10.1002\/ajh.70083","journal-title":"Am J Hematol"},{"key":"6784_CR11","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R et al (2016) The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391\u20132405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544","journal-title":"Blood"},{"key":"6784_CR12","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140:1345\u20131377. https:\/\/doi.org\/10.1182\/blood.2022016867","journal-title":"Blood"},{"key":"6784_CR13","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129:424\u2013447. https:\/\/doi.org\/10.1182\/blood-2016-08-733196","journal-title":"Blood"},{"key":"6784_CR14","doi-asserted-by":"publisher","first-page":"e233","DOI":"10.1016\/j.clml.2021.09.019","volume":"22","author":"C Lalayanni","year":"2022","unstructured":"Lalayanni C, Gavriilaki E, Athanasiadou A et al (2022) Secondary acute myeloid leukemia (sAML): similarly dismal outcomes of AML after an antecedent hematologic disorder and therapy related AML. Clin Lymphoma Myeloma Leuk 22:e233\u2013e240. https:\/\/doi.org\/10.1016\/j.clml.2021.09.019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"6784_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00558-5","volume":"11","author":"C Rautenberg","year":"2021","unstructured":"Rautenberg C, St\u00f6lzel F, R\u00f6llig C et al (2021) Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia. Blood Cancer J 11:164. https:\/\/doi.org\/10.1038\/s41408-021-00558-5","journal-title":"Blood Cancer J"},{"key":"6784_CR16","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","volume":"383","author":"AH Wei","year":"2020","unstructured":"Wei AH, D\u00f6hner H, Pocock C et al (2020) Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission. N Engl J Med 383:2526\u20132537. https:\/\/doi.org\/10.1056\/NEJMoa2004444","journal-title":"N Engl J Med"},{"key":"6784_CR17","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1182\/blood-2024-198362","volume":"144","author":"P Krishnamurthy","year":"2024","unstructured":"Krishnamurthy P, Houghton K, Lorenz N et al (2024) Real-world treatment patterns and outcomes with oral azacitidine maintenance therapy in patients with acute myeloid leukemia. Blood 144:2425. https:\/\/doi.org\/10.1182\/blood-2024-198362","journal-title":"Blood"},{"key":"6784_CR18","doi-asserted-by":"publisher","first-page":"e287","DOI":"10.1016\/S2352-3026(24)00034-6","volume":"11","author":"A Bazinet","year":"2024","unstructured":"Bazinet A, Kantarjian H, Bataller A et al (2024) Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial. Lancet Haematol 11:e287\u2013e298. https:\/\/doi.org\/10.1016\/S2352-3026(24)00034-6","journal-title":"Lancet Haematol"},{"key":"6784_CR19","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.2217\/fon-2022-0450","volume":"18","author":"V Ivanov","year":"2022","unstructured":"Ivanov V, Yeh S-P, Mayer J et al (2022) Design of the VIALE-M phase III trial of venetoclax and oral azacitidine maintenance therapy in acute myeloid leukemia. Future Oncol 18:2879\u20132889. https:\/\/doi.org\/10.2217\/fon-2022-0450","journal-title":"Future Oncol"},{"key":"6784_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2020.102275","volume":"30","author":"Q Wang","year":"2020","unstructured":"Wang Q, Tardi P, Sadowski N et al (2020) Pharmacokinetics, drug metabolism, and tissue distribution of CPX-351 in animals. Nanomedicine 30:102275. https:\/\/doi.org\/10.1016\/j.nano.2020.102275","journal-title":"Nanomedicine"},{"key":"6784_CR21","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1159\/000518356","volume":"66","author":"S Perrone","year":"2021","unstructured":"Perrone S, Ortu La Barbera E, Viola F et al (2021) A relapsing meningeal acute myeloid leukaemia FLT3-ITD\u2009+\u2009responding to gilteritinib. Chemotherapy 66:134\u2013138. https:\/\/doi.org\/10.1159\/000518356","journal-title":"Chemotherapy"},{"key":"6784_CR22","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/1097-0142(19930715)72:2\/253C439::aid-cncr2820720220\/253E3.0.co;2-4","volume":"72","author":"E Morra","year":"1993","unstructured":"Morra E, Lazzarino M, Brusamolino E et al (1993) The role of systemic high-dose cytarabine in the treatment of central nervous system leukemia. Clinical results in 46 patients. Cancer 72:439\u2013445. https:\/\/doi.org\/10.1002\/1097-0142(19930715)72:2\/253C439::aid-cncr2820720220\/253E3.0.co;2-4","journal-title":"Cancer"},{"key":"6784_CR23","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1007\/s11864-022-01032-5","volume":"23","author":"SY Wu","year":"2022","unstructured":"Wu SY, Short NJ, Nasr L et al (2022) Central nervous system prophylaxis and treatment in acute leukemias. Curr Treat Options in Oncol 23:1829\u20131844. https:\/\/doi.org\/10.1007\/s11864-022-01032-5","journal-title":"Curr Treat Options in Oncol"},{"key":"6784_CR24","doi-asserted-by":"publisher","first-page":"5387","DOI":"10.1007\/s00277-024-06106-y","volume":"103","author":"K Kouidri","year":"2024","unstructured":"Kouidri K, Acker F, Toenges R et al (2024) Central nervous system relapse after allogeneic HCT in FLT3-mutated AML. Ann Hematol 103:5387\u20135393. https:\/\/doi.org\/10.1007\/s00277-024-06106-y","journal-title":"Ann Hematol"},{"key":"6784_CR25","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1016\/j.bbmt.2019.12.073","volume":"26","author":"DH Ryan","year":"2020","unstructured":"Ryan DH, Newell LF, Ritchie EK et al (2020) Outcomes in patients with acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) who achieved remission with CPX-351 versus 7\u2009+\u20093: phase 3 exploratory analysis. Biol Blood Marrow Transplant 26:S9\u2013S10. https:\/\/doi.org\/10.1016\/j.bbmt.2019.12.073","journal-title":"Biol Blood Marrow Transplant"},{"key":"6784_CR26","doi-asserted-by":"publisher","first-page":"3842","DOI":"10.1182\/blood-2019-124516","volume":"134","author":"DH Ryan","year":"2019","unstructured":"Ryan DH, Newell LF, Ritchie EK et al (2019) Outcomes in patients with acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) who achieved remission with CPX-351 versus 7\u2009+\u20093: phase 3 exploratory analysis. Blood 134:3842. https:\/\/doi.org\/10.1182\/blood-2019-124516","journal-title":"Blood"},{"key":"6784_CR27","doi-asserted-by":"publisher","first-page":"e481","DOI":"10.1016\/S2352-3026(21)00134-4","volume":"8","author":"JE Lancet","year":"2021","unstructured":"Lancet JE, Uy GL, Newell LF et al (2021) CPX-351 versus 7\u2009+\u20093 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol 8:e481\u2013e491. https:\/\/doi.org\/10.1016\/S2352-3026(21)00134-4","journal-title":"Lancet Haematol"},{"key":"6784_CR28","doi-asserted-by":"publisher","first-page":"6540","DOI":"10.1200\/JCO.2024.42.16_suppl.6540","volume":"42","author":"M Sandhu","year":"2024","unstructured":"Sandhu M, Ashok Kumar P, Shi CW et al (2024) Evaluation of treatment outcomes with CPX-351 in adults with AML: A meta-analysis. JCO 42:6540\u20136540. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.6540","journal-title":"JCO"},{"key":"6784_CR29","doi-asserted-by":"publisher","first-page":"e70005","DOI":"10.1002\/hon.70005","volume":"43","author":"C Riva","year":"2025","unstructured":"Riva C, Minetto P, Chies M et al (2025) Comparing outcomes between CPX-351 and Fludarabine-Based induction in secondary acute myeloid leukemia in the Real-World setting: the prognostic role of measurable residual disease. Hematol Oncol 43:e70005. https:\/\/doi.org\/10.1002\/hon.70005","journal-title":"Hematol Oncol"},{"key":"6784_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01274-0","volume":"15","author":"C Rautenberg","year":"2025","unstructured":"Rautenberg C, Middeke JM, R\u00f6llig C et al (2025) Real-world experience with first-line CPX-351 treatment in patients with acute myeloid leukemia \u2013 long-term follow-up with focus on younger patients. Blood Cancer J 15:60. https:\/\/doi.org\/10.1038\/s41408-025-01274-0","journal-title":"Blood Cancer J"},{"key":"6784_CR31","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1182\/bloodadvances.2020003159","volume":"5","author":"E Chiche","year":"2021","unstructured":"Chiche E, Rahm\u00e9 R, Bertoli S et al (2021) Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort. Blood Adv 5:176\u2013184. https:\/\/doi.org\/10.1182\/bloodadvances.2020003159","journal-title":"Blood Adv"},{"key":"6784_CR32","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1182\/bloodadvances.2024014279","volume":"9","author":"T Cluzeau","year":"2025","unstructured":"Cluzeau T, Guolo F, Chiche E et al (2025) Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OS. Blood Adv 9:752\u2013758. https:\/\/doi.org\/10.1182\/bloodadvances.2024014279","journal-title":"Blood Adv"},{"key":"6784_CR33","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1182\/blood.2021013626","volume":"138","author":"M Heuser","year":"2021","unstructured":"Heuser M, Freeman SD, Ossenkoppele GJ et al (2021) 2021 update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood 138:2753\u20132767. https:\/\/doi.org\/10.1182\/blood.2021013626","journal-title":"Blood"},{"key":"6784_CR34","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","volume":"6","author":"NJ Short","year":"2020","unstructured":"Short NJ, Zhou S, Fu C et al (2020) Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: A systematic review and Meta-analysis. JAMA Oncol 6:1890. https:\/\/doi.org\/10.1001\/jamaoncol.2020.4600","journal-title":"JAMA Oncol"},{"key":"6784_CR35","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/bmt.2014.9","volume":"49","author":"C Anthias","year":"2014","unstructured":"Anthias C, Dignan FL, Morilla R et al (2014) Pre-transplant MRD predicts outcome following reduced-intensity and myeloablative allogeneic hemopoietic SCT in AML. Bone Marrow Transplant 49:679\u2013683. https:\/\/doi.org\/10.1038\/bmt.2014.9","journal-title":"Bone Marrow Transplant"},{"key":"6784_CR36","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41375-024-02497-z","volume":"39","author":"C Orvain","year":"2025","unstructured":"Orvain C, Milano F, Rodr\u00edguez-Arbol\u00ed E et al (2025) Relationship between donor source, pre-transplant measurable residual disease, and outcome after allografting for adults with acute myeloid leukemia. Leukemia 39:381\u2013390. https:\/\/doi.org\/10.1038\/s41375-024-02497-z","journal-title":"Leukemia"},{"key":"6784_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14041254","volume":"14","author":"V Mezzanotte","year":"2025","unstructured":"Mezzanotte V, Paterno G, Cerroni I et al (2025) Use of primary prophylaxis with G-CSF in acute myeloid leukemia patients undergoing intensive chemotherapy does not affect quality of response. J Clin Med 14:1254. https:\/\/doi.org\/10.3390\/jcm14041254","journal-title":"J Clin Med"},{"key":"6784_CR38","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1182\/blood.2021014401","volume":"139","author":"JP Bewersdorf","year":"2022","unstructured":"Bewersdorf JP, Patel KK, Goshua G et al (2022) Cost-effectiveness of liposomal cytarabine\/daunorubicin in patients with newly diagnosed acute myeloid leukemia. Blood 139:1766\u20131770. https:\/\/doi.org\/10.1182\/blood.2021014401","journal-title":"Blood"},{"key":"6784_CR39","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2147\/CEOR.S342303","volume":"14","author":"K Price","year":"2022","unstructured":"Price K, Cao Z, Lipkin C, et al et al (2022) Comparison of hospital length of stay and supportive care utilization between patients treated with CPX-351 and 7\u2009+\u20093 for Therapy-Related acute myeloid leukemia or acute myeloid leukemia with Myelodysplasia-Related changes. Clinicoecon Outcomes Res 14:21\u201334. https:\/\/doi.org\/10.2147\/CEOR.S342303","journal-title":"Clinicoecon Outcomes Res"},{"key":"6784_CR40","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1177\/10781552211046574","volume":"28","author":"W Li","year":"2022","unstructured":"Li W, Richter K, Lee J et al (2022) Safety and feasibility of outpatient high-dose cytarabine and intermediate-dose cytarabine for consolidation therapy in acute myeloid leukemia. J Oncol Pharm Pract 28:1812\u20131818. https:\/\/doi.org\/10.1177\/10781552211046574","journal-title":"J Oncol Pharm Pract"},{"key":"6784_CR41","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1111\/ejh.14094","volume":"111","author":"I Sljivic","year":"2023","unstructured":"Sljivic I, Fulford A, Ho J et al (2023) Outpatient consolidation chemotherapy with intermediate dose cytarabine has similar survival and relapses rates in acute myeloid leukemia as compared to high dose cytarabine: a single center analysis. Eur J Haematol 111:888\u2013894. https:\/\/doi.org\/10.1111\/ejh.14094","journal-title":"Eur J Haematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06784-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06784-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06784-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T16:04:05Z","timestamp":1771949045000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06784-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":41,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["6784"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06784-w","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"assertion":[{"value":"30 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and the Good Clinical Practice guidelines of the International Council for Harmonization. The protocol and related documents were approved by the Ethics Committee of the coordinating center (Lazio 1).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"110"}}